REPORT PURSUANT TO SECTION 28a OF THE DANISH SECURITIES TRADING ACT

Copenhagen, Denmark; October 14, 2011 – Pursuant to Section 28a of the Danish Securities Trading Act, Genmab A/S (OMX: GEN) shall make public information on transactions by managerial employees and their related parties involving Genmab shares and related instruments, as follows:

Name: Nedjad Losic
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ ISIN: DK0010272202
Description: Warrants
Transaction: Grant
Trading date: October 14, 2011
Market: NASDAQ OMX Copenhagen A/S
Number: 3,000
Value: DKK 50,790

The exercise price for each warrant is DKK 31.75. Each warrant entitles the owner to subscribe one share of nominally DKK 1. On the basis of an exercise price of DKK 31.75 and by application of the Black-Scholes formula, the average value of each warrant can be calculated as DKK 16.93 based on an interest rate of 1.3091% and the historical volatility of Genmab A/S shares calculated at 61.21%.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, Arzerra® (ofatumumab), was approved to treat chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com